AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31191639 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging resting‐state sessions (before and after training)
Number of subjects: 0
Study 28425239 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week thoracic spine stabilization exercise program
Number of subjects: 53
Study 28425239 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 53
Study 25542416 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency pedaling rate (LFTr, 35 rpm)
Number of subjects: 16
Study 25542416 — intervention group
Group type: COMPARATOR
Intervention: High frequency pedaling rate (HFTr, 75 rpm)
Number of subjects: 16
Study 25542416 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 rpm pedaling rate
Number of subjects: 16
Study 25542416 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 rpm pedaling rate
Number of subjects: 16
Study 23884017 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) of abdominal muscles during cough training for 6 weeks, 5 days per week (5 sets of 10 coughs per day)
Number of subjects: 15
Study 23884017 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) of abdominal muscles
Number of subjects: 15
Study 23884017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough training
Number of subjects: 15
Study 21110014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 10 mg
Number of subjects: 63
Study 21110014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 20 mg
Number of subjects: 63
Study 21110014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 40 mg
Number of subjects: 63
Study 21110014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) high-dose
Number of subjects: 63
Study 21110014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) low-, middle-, and high-dose
Number of subjects: 63
Study 19299273 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia (LA)
Number of subjects: 72
Study 19299273 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 72
Study 17143898 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Number of subjects: 64
Study 17143898 — intervention group
Group type: COMPARATOR
Intervention: C‐CF training
Number of subjects: 64
Study 17313003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-three-needle therapy
Number of subjects: 380
Study 17313003 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 380
Study 17313003 — intervention group
Group type: COMPARATOR
Intervention: Medication (aspirin-DL-lysine plus saline)
Number of subjects: 380
Study 14564194 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of dialysis
Number of subjects: 0
Study 14564194 — intervention group
Group type: COMPARATOR
Intervention: High dose of dialysis
Number of subjects: 0
Study 14564194 — intervention group
Group type: COMPARATOR
Intervention: Low flux dialyzer
Number of subjects: 0
Study 14564194 — intervention group
Group type: COMPARATOR
Intervention: High flux dialyzer
Number of subjects: 0
Study 10027500 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger-temperature biofeedback
Number of subjects: 0
Study 10027500 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine (calcium channel blocker)
Number of subjects: 0
Study 10027500 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 10027500 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific behavioral control group
Number of subjects: 0
Study 8933115 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaked barley flapjack
Number of subjects: 12
Study 8933115 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley flour flapjack
Number of subjects: 12
Study 8933115 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaked barley
Number of subjects: 12
Study 1719730 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40
Number of subjects: 0
Study 1719730 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch 200
Number of subjects: 0
Study 1719730 — intervention group
Group type: COMPARATOR
Intervention: Sham-hemodilution
Number of subjects: 0
Study 7015670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinoxacin
Number of subjects: 0
Study 31377976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 192
Study 31377976 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 192
Study 30260088 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 30260088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27575450 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg sugammadex
Number of subjects: 180
Study 27575450 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg sugammadex
Number of subjects: 180
Study 27575450 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg sugammadex
Number of subjects: 180
Study 26647750 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Number of subjects: 60
Study 26647750 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 26647750 — intervention group
Group type: COMPARATOR
Intervention: Micropore (placebo)
Number of subjects: 60
Study 23975857 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study 23975857 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine
Number of subjects: 0
Study 21106702 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive intensive treadmill training with virtual obstacles (TT + VR)
Number of subjects: 20
Study 20158058 — intervention group
Group type: EXPERIMENTAL
Intervention: Home tray bleaching product
Number of subjects: 50
Study 20158058 — intervention group
Group type: EXPERIMENTAL
Intervention: In surgery tray bleaching product
Number of subjects: 50
Study 20158058 — intervention group
Group type: EXPERIMENTAL
Intervention: In surgery power bleaching product with light activation
Number of subjects: 50
Study 20158058 — intervention group
Group type: EXPERIMENTAL
Intervention: In surgery power bleaching product without light activation
Number of subjects: 50
Study 20158058 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (water)
Number of subjects: 50
Study 17560166 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine
Number of subjects: 311
Study 17560166 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 311
Study 15500306 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of therapist competence
Number of subjects: 49
Study 15500306 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists rated as more competent
Number of subjects: 49
Study 11310462 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Tubigrip bandage (DTG)
Number of subjects: 400
Study 11310462 — intervention group
Group type: COMPARATOR
Intervention: No Double Tubigrip bandage
Number of subjects: 400
Study 9152262 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and consultation in continuous quality improvement and office prevention systems
Number of subjects: 6830
Study 9152262 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable attitudes toward preventive services
Number of subjects: 6830
Study 9152262 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors related to the provision of preventive services
Number of subjects: 6830
Study 7962892 — intervention group
Group type: EXPERIMENTAL
Intervention: Maritally focused stress interview
Number of subjects: 34
Study 7962892 — intervention group
Group type: COMPARATOR
Intervention: Neutral talking control task
Number of subjects: 34
Study 3307518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 1.5 mg/hour
Number of subjects: 61
Study 3307518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 3.0 mg/hour
Number of subjects: 61
Study 3307518 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 61
Study 30827725 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal cytology
Number of subjects: 75
Study 30827725 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal HPV16/18 testing
Number of subjects: 75
Study 30827725 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of anal HSIL
Number of subjects: 75
Study 30827725 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 75
Study 29183347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (motivational counselling combined with tailored nicotine replacement therapy)
Number of subjects: 150
Study 29183347 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study 26483244 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-29 pack-year current smokers
Number of subjects: 2283
Study 23732949 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement amplitude of 4° with ID 6
Number of subjects: 0
Study 23732949 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement amplitude of 8° and 16°
Number of subjects: 0
Study 23732949 — intervention group
Group type: EXPERIMENTAL
Intervention: High ID movements
Number of subjects: 0
Study 23732949 — intervention group
Group type: EXPERIMENTAL
Intervention: 4° amplitude
Number of subjects: 0
Study 20649448 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training in a gaming format
Number of subjects: 51
Study 20649448 — intervention group
Group type: COMPARATOR
Intervention: Regular WM training (not in a gaming format)
Number of subjects: 51
Study 19874084 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) for hemiplegic foot dorsiflexor muscles, 4 weeks, 5 days a week, total of 20 sessions
Number of subjects: 40
Study 19874084 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 40
Study 19874084 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) combined with conventional rehabilitation
Number of subjects: 40
Study 19874084 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) and conventional rehabilitation
Number of subjects: 40
Study 17105327 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical orthopedic plate (IO+) until surgical closure of the soft palate at 52 weeks
Number of subjects: 54
Study 17105327 — intervention group
Group type: COMPARATOR
Intervention: No presurgical orthopedics (IO-)
Number of subjects: 54
Study 14990633 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/d
Number of subjects: 1037
Study 14990633 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/d
Number of subjects: 1037
Study 14990633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1037
Study 14990633 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (500 mg/d and 250 mg/d)
Number of subjects: 1037
Study 14990633 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib maintenance effect
Number of subjects: 1037
Study 12019407 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral fluconazole
Number of subjects: 130
Study 12019407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 9595000 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 20
Study 9595000 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 20
Study 7539182 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective alpha 1 blockers
Number of subjects: 0
Study 2485285 — intervention group
Group type: COMPARATOR
Intervention: Group C (money contingent on nonimpaired performance)
Number of subjects: 24
Study 2485285 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (less valuable outcome - information only)
Number of subjects: 24
Study 2485285 — intervention group
Group type: EXPERIMENTAL
Intervention: Group R (money scheduled randomly)
Number of subjects: 24
Study 2485285 — intervention group
Group type: EXPERIMENTAL
Intervention: Group N (no outcome for performance)
Number of subjects: 24
Study 336306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (0.1 mg, 0.2 mg, or 0.4 mg)
Number of subjects: 20
Study 336306 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.15 mg)
Number of subjects: 20
Study 336306 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo propellant
Number of subjects: 20
Study 30820962 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated dialyzers
Number of subjects: 6
Study 30820962 — intervention group
Group type: COMPARATOR
Intervention: Non-coated dialyzers
Number of subjects: 6
Study 27326658 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 135
Study 27326658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 25768066 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke survivors with aspiration
Number of subjects: 30
Study 25768066 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke survivors without aspiration
Number of subjects: 30
Study 25768066 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 30
Study 23838533 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-disclosure health support (WSHS) system
Number of subjects: 193
Study 23838533 — intervention group
Group type: COMPARATOR
Intervention: Email health support (EHS)
Number of subjects: 193
Study 22117299 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional condition encouraging grasping the topic of the text
Number of subjects: 798
Study 22117299 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional condition encouraging remembering details of the text
Number of subjects: 798
Study 22117299 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 798
Study 19815265 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily with breakfast (de novo treatment)
Number of subjects: 661
Study 19815265 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily with breakfast (continuing treatment)
Number of subjects: 661
Study 19815265 — intervention group
Group type: COMPARATOR
Intervention: Silodosin (de novo treatment)
Number of subjects: 661
Study 19815265 — intervention group
Group type: COMPARATOR
Intervention: Silodosin (continuing treatment)
Number of subjects: 661
Study 17610271 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free Vaginal Tape (TVT)
Number of subjects: 3
Study 17610271 — intervention group
Group type: COMPARATOR
Intervention: Open Burch colposuspension (OBC)
Number of subjects: 3
Study 17610271 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic colposuspension with sutures (LCS)
Number of subjects: 3
Study 17610271 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic colposuspension with mesh and staples (LCM)
Number of subjects: 3
Study 15472782 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study 15472782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10839062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive enhancement program 'Memories, Memories, Can We Improve Ours?' (8 sessions)
Number of subjects: 19
Study 8930719 — intervention group
Group type: EXPERIMENTAL
Intervention: Neer's technique
Number of subjects: 20
Study 8930719 — intervention group
Group type: COMPARATOR
Intervention: Modified technique (deltoid origin spared)
Number of subjects: 20
Study 14621837 — intervention group
Group type: EXPERIMENTAL
Intervention: NON-HBD
Number of subjects: 34
Study 14621837 — intervention group
Group type: COMPARATOR
Intervention: HBD
Number of subjects: 34
Study 4083300 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour sustained-release theophylline formulation, Uniphyl
Number of subjects: 9
Study 4083300 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily compound, Theo-Dur
Number of subjects: 9
Study 4083300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31158450 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pivotal trials (20 randomized controlled trials and 15 single-arm trials)
Number of subjects: 100
Study 31158450 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pivotal trials
Number of subjects: 100
Study 28799226 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of educational outreach visits with feedback on prescribing and the development of a working procedure on medication reviews (MRs). Follow-up duration was 9 months.
Number of subjects: 119910
Study 28799226 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 119910
Study 28799226 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (same as above).
Number of subjects: 119910
Study 25996838 — intervention group
Group type: EXPERIMENTAL
Intervention: HBvaxPRO® (10 μg)
Number of subjects: 204
Study 25996838 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix B™
Number of subjects: 204
Study 22819388 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose-rate brachytherapy
Number of subjects: 86
Study 22819388 — intervention group
Group type: EXPERIMENTAL
Intervention: Central review of postimplantation CT scans
Number of subjects: 86
Study 22303706 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) 1 mL/kg intravenously before induction of anesthesia and in priming solution
Number of subjects: 20
Study 22303706 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study 19575919 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ
Number of subjects: 260
Study 19575919 — intervention group
Group type: COMPARATOR
Intervention: AcrySof Natural
Number of subjects: 260
Study 16740846 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant (dexamphetamine or methylphenidate)
Number of subjects: 108
Study 16740846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 16740846 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant (post-trial management)
Number of subjects: 108
Study 16740846 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant (nonresponders)
Number of subjects: 108
Study 16740846 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttrial management
Number of subjects: 108
Study 16740846 — intervention group
Group type: EXPERIMENTAL
Intervention: N-of-1 trials (overall management change)
Number of subjects: 108
Study 15468546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hemodilution with colloids and crystalloids; donor packed red blood cells used at hemoglobin level below 80 g/l.
Number of subjects: 116
Study 15468546 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation of autoblood and hardware-based reinfusion of autoerythrocytes.
Number of subjects: 116
Study 15468546 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of hemoglobin below 90 g/l.
Number of subjects: 116
Study 15468546 — intervention group
Group type: COMPARATOR
Intervention: Control group with autoblood preparation and limited infusion volume before aorta clipping.
Number of subjects: 116
Study 11142483 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-chemotherapy induction treatment
Number of subjects: 3948
Study 11142483 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN maintenance therapy
Number of subjects: 3948
Study 11142483 — intervention group
Group type: EXPERIMENTAL
Intervention: All IFN trials combined
Number of subjects: 3948
Study 11142483 — intervention group
Group type: COMPARATOR
Intervention: Control (chemotherapy alone or without treatment)
Number of subjects: 3948
Study 9294121 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-lipid complexes (GL-67:DOPE)
Number of subjects: 0
Study 9294121 — intervention group
Group type: COMPARATOR
Intervention: DNA alone (pCF1-CFTR)
Number of subjects: 0
Study 9294121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DNA-lipid and DNA alone
Number of subjects: 0
Study 8204943 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg/day
Number of subjects: 369
Study 8204943 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg/day
Number of subjects: 369
Study 8204943 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg/day
Number of subjects: 369
Study 3011530 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-RH (25 micrograms as a single i.v. bolus)
Number of subjects: 8
Study 3011530 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 8
Study 3402181 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of metoclopramide (loading dose of 3 mg/kg followed by 0.5 mg/kg/hr for 12 hours)
Number of subjects: 27
Study 3402181 — intervention group
Group type: COMPARATOR
Intervention: Bolus doses of metoclopramide (2 mg/kg added to each bolus dose)
Number of subjects: 27
Study 3402181 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of metoclopramide (placebo of 5% dextrose injection)
Number of subjects: 27
Study 3402181 — intervention group
Group type: COMPARATOR
Intervention: Bolus doses of metoclopramide (placebo of 5% dextrose injection)
Number of subjects: 27
Study 29658353 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5‐mg intravenous injection, administered 1 week postoperatively)
Number of subjects: 113
Study 29658353 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered 1 week postoperatively)
Number of subjects: 113
Study 29141679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular oxytocin (10 IU in 1 mL)
Number of subjects: 1000
Study 29141679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin (10 IU in 1 mL given slowly over 1 min)
Number of subjects: 1000
Study 29141679 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenous injection (1 mL 0.9% saline given slowly)
Number of subjects: 1000
Study 29141679 — intervention group
Group type: COMPARATOR
Intervention: Placebo intramuscular injection (1 mL 0.9% saline)
Number of subjects: 1000
Study 26465983 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 863
Study 26465983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 863